Zobrazeno 1 - 10
of 127
pro vyhledávání: '"Claudia Maletzki"'
Autor:
Thomas Freitag, Philipp Kaps, Justus Ramtke, Sarah Bertels, Emily Zunke, Björn Schneider, Anne-Sophie Becker, Dirk Koczan, Daniel Dubinski, Thomas M. Freiman, Felix Wittig, Burkhard Hinz, Mike-Andrew Westhoff, Hannah Strobel, Franziska Meiners, Daniel Wolter, Nadja Engel, Sascha Troschke-Meurer, Wendy Bergmann-Ewert, Susanne Staehlke, Annabell Wolff, Florian Gessler, Christian Junghanss, Claudia Maletzki
Publikováno v:
npj Precision Oncology, Vol 8, Iss 1, Pp 1-17 (2024)
Abstract Here, we show that combined use of the EZH2 inhibitor GSK126 and the CDK4/6 inhibitor abemaciclib synergistically enhances antitumoral effects in preclinical GBM models. Dual blockade led to HIF1α upregulation and CalR translocation, accomp
Externí odkaz:
https://doaj.org/article/48c31a82a0d54c5ea79c6f99d70e3d61
Autor:
Annika Kayser, Annabell Wolff, Peggy Berlin, Lara Duehring, Larissa Henze, Ralf Mundkowski, Wendy Bergmann, Brigitte Müller-Hilke, Charlotte Wagner, Maja Huehns, Sonja Oehmcke-Hecht, Claudia Maletzki
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-12 (2024)
Abstract Thromboembolic events are complications in cancer patients and hypercoagulability has been linked to the tissue factor (TF) pathway, making this an attractive target. Here, we investigated the effects of chemotherapeutics and CDK inhibitors
Externí odkaz:
https://doaj.org/article/0e2a2b478c654978834942a660548817
Autor:
Annabell Wolff, Paula Krone, Johanna Maennicke, Julia Henne, Sonja Oehmcke-Hecht, Caterina Redwanz, Wendy Bergmann-Ewert, Christian Junghanss, Larissa Henze, Claudia Maletzki
Publikováno v:
Translational Oncology, Vol 47, Iss , Pp 102053- (2024)
Background: The CDK4/6 inhibitor abemaciclib is an FDA-approved agent and induces T-cell-mediated immunity. Previously, we confirmed the therapeutic potential of abemaciclib on mismatch repair-deficient (dMMR) tumors in mice. Here, we applied a proph
Externí odkaz:
https://doaj.org/article/eac5a1c76e4a4c1983f6fdb028e98cf2
Autor:
Falko Lange, Richard Gade, Anne Einsle, Katrin Porath, Gesine Reichart, Claudia Maletzki, Björn Schneider, Christian Henker, Daniel Dubinski, Michael Linnebacher, Rüdiger Köhling, Thomas M. Freiman, Timo Kirschstein
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
BackgroundThe differentiation of high-grade glioma and brain tumors of an extracranial origin is eminent for the decision on subsequent treatment regimens. While in high-grade glioma, a surgical resection of the tumor mass is a fundamental part of cu
Externí odkaz:
https://doaj.org/article/dbe6cf8eeb524090a81b93767e6a50e6
Autor:
Claudia Maletzki, Vivica Freiin Grote, Friederike Kalle, Thoralf Kleitke, Annette Zimpfer, Anne-Sophie Becker, Wendy Bergmann-Ewert, Anika Jonitz-Heincke, Rainer Bader, Brigitte Vollmar, Stephan Hackenberg, Agmal Scherzad, Robert Mlynski, Daniel Strüder
Publikováno v:
Cell Death Discovery, Vol 9, Iss 1, Pp 1-11 (2023)
Abstract High hydrostatic pressure specifically devitalizes cells and tissues without major changes in their molecular structure. Hence, high hydrostatic pressure may enhance the development of whole-cell anti-tumor vaccines, representing tumor heter
Externí odkaz:
https://doaj.org/article/b841701ec51f4facbc107285f39da9cf
Autor:
Paula Krone, Annabell Wolff, Julia Teichmann, Johanna Maennicke, Julia Henne, Leonie Engster, Inken Salewski, Wendy Bergmann, Christian Junghanss, Claudia Maletzki
Publikováno v:
OncoImmunology, Vol 12, Iss 1 (2023)
ABSTRACTWide-spread cancer-related immunosuppression often curtails immune-mediated antitumoral responses. Immune-checkpoint inhibitors (ICIs) have become a state-of-the-art treatment modality for mismatch repair-deficient (dMMR) tumors. Still, the i
Externí odkaz:
https://doaj.org/article/74275ddb60e74d7fb08e87f87a7b42d8
Autor:
Charlotte Linke, Thomas Freitag, Christin Riess, Jana Vanessa Scheffler, Katharina del Moral, Nina Schoenwaelder, Tomas Fiedler, Adina Fiebig, Philipp Kaps, Daniel Dubinski, Björn Schneider, Wendy Bergmann, Carl Friedrich Classen, Claudia Maletzki
Publikováno v:
Cancer Cell International, Vol 23, Iss 1, Pp 1-18 (2023)
Abstract Background Arginine auxotrophy constitutes a shortcoming for ~ 30% of glioblastoma multiforme (GBM). Indeed, arginine-depleting therapy using arginine deiminase from Streptococcus pyogenes (SpyADI) has proven activity against GBM in preclini
Externí odkaz:
https://doaj.org/article/b688d5f6f21b43c69fa8ffaf7d1c4143
Autor:
Said Kdimati, Clemens Christoph, Änne Glass, Nadja Engel, Desiree-Louise Dräger, Claudia Maletzki, Anne-Sophie Becker, Annette Zimpfer
Publikováno v:
International Journal of Molecular Sciences, Vol 25, Iss 6, p 3492 (2024)
Upper tract urothelial carcinoma (UTUC) accounts for 5–10% of all UCs. Immune checkpoint inhibitors (ICIs) have been established for UCs. The prognostic and predictive potential of programmed cell death ligand 1 (PD-L1) expression to stratify patie
Externí odkaz:
https://doaj.org/article/d779168de4b94a03a011ac95611f7b60
Autor:
Anne-Sophie Becker, Cornelius Kluge, Carsten Schofeld, Annette Helene Zimpfer, Björn Schneider, Daniel Strüder, Caterina Redwanz, Julika Ribbat-Idel, Christian Idel, Claudia Maletzki
Publikováno v:
Cancers, Vol 15, Iss 23, p 5597 (2023)
The 5-year survival rate for head and neck squamous cell carcinoma (HNSCC) is approximately 65%. In addition to radio-chemotherapy, immunotherapy is an approach in the treatment of advanced HNSCC. A better understanding of the immune context would al
Externí odkaz:
https://doaj.org/article/a2186475612c4183a12ee6f86fe8ff9d
Autor:
Sonja Oehmcke-Hecht, Claudia Maletzki, Surabhi Surabhi, Nikolai Siemens, Valeria Khaimov, Lisa Marie John, Sina Mariella Peter, Sven Hammerschmidt, Bernd Kreikemeyer
Publikováno v:
Journal of Innate Immunity, Pp 1-17 (2022)
The coagulation and contact systems are parts of the innate immune system as they prevent bleeding and dissemination of pathogens and also contribute to microbial killing by inflammatory reactions and the release of antimicrobial peptides. Here, we i
Externí odkaz:
https://doaj.org/article/77e253fcba3b43a593238199fcb909d3